WebOct 13, 2024 · Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec's cash reserves by € 250 million in total. Evotec has developed a unique strategy to become the global leading platform company for the modality-agnostic development of innovative first-in-class and best-in … WebMay 17, 2024 · Upon commercialisation, there will be a profit-sharing arrangement between the two companies, with the split dependent upon Evotec’s participation in the clinical development programme. In conjunction with the agreement, Evotec has committed to a strategic € 20 m equity investment in Sernova (approx. CAD$ 27 m at an €/CAD$ fx rate …
Evotec Issues Update On Cyber Attack - rttnews.com
WebOct 13, 2024 · Mubadala Investment Company on Tuesday announced that it is pumping 200 million euros ($235.71 million) into Evotec, a German pharmaceutical company that specialises in drug discovery solutions. Evotec said that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. WebFeb 13, 2024 · Hamburg-based Evotec, a life sciences company, announced on Friday, February 10, that it has raised an unsecured loan facility of €150M from the European Investment Bank (EIB).. Evotec says it will use the funds to accelerate its R&D activities, equity investments, and the building of the new J.POD biologics manufacturing facility … know domain owner
EVOTEC SE Aktie News: EVOTEC SE am Vormittag im Plus
WebEvotec SE announced today that Cyprotex US, LLC, the US site of Cyprotex a wholly owned subsidiary of Evotec, has completed its relocation from…. Liked by Sabine Den Hartogh. At Evotec CRISPR Cas9 is widely used. We use the technology to drive its target identification and validation platforms as well as aid the…. Liked by Sabine Den Hartogh. WebApr 10, 2024 · (RTTNews) - Evotec SE (EVO) issued an update on the cyber attack that was detected on 6 April, 2024. The company noticed unusual activity in one of its IT … WebApr 6, 2024 · Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. redact function